(Reduce img size in main page.) |
(Center images naturally; remove extra annotations.) |
||
Line 14: | Line 14: | ||
div.title { | div.title { | ||
− | + | margin: 20px 0; | |
+ | } | ||
+ | |||
+ | div.title > a > img { | ||
+ | margin: auto; | ||
} | } | ||
Line 29: | Line 33: | ||
div.content img { | div.content img { | ||
height: auto; | height: auto; | ||
− | width: | + | width: 150px; |
} | } | ||
Line 57: | Line 61: | ||
<div class="title" style="margin:auto"> | <div class="title" style="margin:auto"> | ||
<a href="https://2017.igem.org/Team:ETH_Zurich"> | <a href="https://2017.igem.org/Team:ETH_Zurich"> | ||
− | <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png | + | <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png"/> |
</a> | </a> | ||
</div> | </div> | ||
Line 63: | Line 67: | ||
<div style="margin:auto;"> | <div style="margin:auto;"> | ||
<a href="#start"> | <a href="#start"> | ||
− | <img src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png | + | <img src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png"> |
</a> | </a> | ||
</div> | </div> | ||
Line 73: | Line 77: | ||
<p>That's why we created CATE: Cancer-Targeting E. coli.</p> | <p>That's why we created CATE: Cancer-Targeting E. coli.</p> | ||
<a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a> | <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a> | ||
− | <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH | + | <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH"> |
</div> | </div> | ||
<div id="second"> | <div id="second"> | ||
− | <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec | + | <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec"> |
<p>CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p> | <p>CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p> | ||
<a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a> | <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a> | ||
Line 84: | Line 88: | ||
<div id="third"> | <div id="third"> | ||
<p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p> | <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p> | ||
− | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND | + | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND"> |
<p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p> | <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p> | ||
<a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a> | <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a> |
Revision as of 04:19, 15 October 2017
![CATE logo](https://static.igem.org/mediawiki/2017/d/d6/T--ETH_Zurich--LogoMinimal.png)
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more![](https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png)
![](https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png)
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.
We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor
![](https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png)
The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.
Design